drugset / Trial / NCT05743764

HU007 in Patients with Dry Eye Syndrome

NCT05743764

Phase 3 Completed 328 enrolled Huons Co., Ltd.
RandomizedFactorialDouble-blindTreatment

Summary

A multicenter, Randomized, Double blind, Restasis®-controlled Non-inferiority, Moisview® Eye Drops Controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients with Dry Eye Syndrome

Timeline

Start
2023-03-23
Primary completion
2024-02-14
Completion
2024-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 0.02 % Other
Subject Cyclosporine Peptide 0.05 % Other
Subject Trehalose Small molecule 3 % Other

Indications